Drug Trial Radar · NCT06849791
A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
Feb 26, 2025
Primary completion
May 8, 2026
Study completion May 8, 2026
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Feb 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will assess the relative bioavailability and effect of food on pharmacokinetics of ABBV-932 oral administration in healthy adult participants.
Conditions
- Healthy Volunteer
Interventions
ABBV-932Drug
Oral Capsule
ABBV-932Drug
Oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Plasma Concentration (Cmax) of ABBV-932Time frame: Up to approximately 6 days
- Time to Cmax (Tmax) of ABBV-932Time frame: Up to approximately 6 days
- Terminal Phase Elimination Rate Constant (Beta) of ABBV-932Time frame: Up to approximately 6 days
- Terminal Phase Elimination Half-Life (t1/2) of ABBV-932Time frame: Up to approximately 6 days
- Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-932Time frame: Up to approximately 6 days
- Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-932Time frame: Up to approximately 6 days
- Number of Participants Experiencing Adverse EventsTime frame: Up to approximately 180 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Acpru /Id# 266649
Grayslake, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.